Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane®) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor.
1. A method for treating breast cancer in an individual, the method comprising:
(a) determining hormone receptor status of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2; and
(b) administering to the individual an effective amount of a composition comprising nanoparticles comprising a taxane and a carrier protein, wherein the hormone receptor status of the individual is negative for estrogen receptor (ER−), progesterone receptor (PR−) and human epidermal growth factor receptor-2 (HER2−).
2. A method for treating breast cancer in an individual, the method comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising a taxane and a carrier protein, wherein negative hormone receptor status of estrogen receptor (ER−), progesterone receptor (PR−), and human epidermal growth factor receptor-2 (HER2−) is used as a basis for selecting the individual to receive treatment.
3. A method of identifying an individual suitable for breast cancer treatment, the method comprising determining hormone receptor status of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2, wherein the individual is identified as suitable for breast cancer treatment with nanoparticles comprising a taxane and a carrier protein if hormone receptor status is negative for estrogen receptor (ER−), progesterone receptor (PR−), and human epidermal growth factor receptor-2 (HER2−).
4. The method of claim 2 , wherein the taxane is paclitaxel.
5. The method of claim 2 , wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.
6. The method of claim 2 , wherein the carrier protein is albumin.
7. The method of claim 6 , wherein the albumin is human serum albumin.
8. The method of claim 6 , wherein the weight ratio of albumin and the paclitaxel in the nanoparticle composition is less than about 9:1.
9. The method of claim 4 , wherein the nanoparticle composition is free of Cremophor.
10. The method of claim 2 , further comprising administering to the individual an effective amount of at least one other chemotherapeutic agent.
11. The method of claim 10 , wherein the at least one other chemotherapeutic agent comprises 5-fluorouracil, epirubicin, and cyclophosphamide.
12. The method of claim 11 , wherein the breast cancer is locally advanced breast cancer.
13. The method of claim 2 , wherein the individual is human.